Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RESTORE KIDS | Other Identifier | AVITA Medical |
Not provided
Not provided
Not provided
In June 2021, the US FDA approved expanded use of the RECELL System for treatment of acute full-thickness thermal burns in patients 1-month of age and older (removing the prior limitation of use in patients younger than 18 years of age).
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biomedical Advanced Research and Development Authority | FED |
Not provided
Not provided
Not provided
Not provided
A prospective, parallel-arm, randomized (1:1) multicenter trial to demonstrate that RECELL treatment of partial-thickness burn injuries, can safely and effectively increase the incidence of Day 10 healing compared with a standardized wound dressing.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RECELL® Autologous Cell Harvesting Device | Experimental | RECELL + Telfa™ Clear and Xeroform™ dressings Conventional autografting (only when indicated) |
|
| Mepilex® Ag Wound Dressing | Active Comparator | Mepilex® Ag Wound Dressing Conventional autografting (only when indicated) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device | Device | Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Index Burns With Day 10 Healing | Day 10 healing will be evaluated by an observer blinded to treatment allocation with confirmation at Day 28 | 10 Days post-treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Day 21 Healing of the Index Burn | Incidence of Day 21 healing of the Index Burn confirmed on Day 28 | Day 21, confirmed on Day 28 |
| Incidence of Conventional Autografting to Achieve Healing of the Index Burn |
Not provided
Inclusion Criteria:
Male or female patients aged 1 through 16 years (inclusive) with a partial-thickness thermal burn injury.
The patient has a thermal burn injury that is:
The Index Burn must be a clean partial-thickness burn injury > or = to 160 cm2 and between 2-20% BSA (inclusive).
The Index Burn may not cover the face, hand, foot or perineum/genitalia (Note: a patient with wounds in these areas may be enrolled but the Index Burn Area may not include these areas).
The patient and/or guardian agrees to comply with all compulsory study procedures and visit schedule.
The patient and/or parent/guardian agrees to abstain from any other treatment for closure of the Index Burn for the duration of the study, unless medically necessary.
The patient and/or parent/guardian agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study.
In the opinion of the investigator, the patient and/or parent/guardian must be able to:
Exclusion Criteria:
Post-Randomization Inclusion Criteria (prior to treatment):
Post-Randomization Exclusion Criteria (prior to treatment):
1. Incidental finding of any pre-randomization exclusion criteria.
Consented subjects who do not meet the post-randomization eligibility criteria and did not receive study treatment will be followed through the Day 28 visit and then withdrawn from the study. The criteria for which exclusion was based will be documented.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arizona Burn Center / Valleywise Health | Phoenix | Arizona | 85008 | United States | ||
| University of South Florida Tampa General Hospital |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | RECELL® Autologous Cell Harvesting Device | RECELL + Telfa™ Clear and Xeroform™ dressings Conventional autografting (only when indicated) RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings. Conventional autografting (only when indicated): When indicated, conventional autografting in accordance with Investigator's standard practice |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 11, 2020 |
Not provided
Not provided
Not provided
Not provided
| Mepilex® Ag Wound Dressing | Combination Product | Application of Mepilex® Ag Wound Dressing |
|
| Conventional autografting (only when indicated) | Procedure | When indicated, conventional autografting in accordance with Investigator's standard practice |
|
Incidence of conventional autografting to achieve healing of the Index Burn
| Through Day 28 |
| Tampa |
| Florida |
| 33606 |
| United States |
| University Medical Center New Orleans | New Orleans | Louisiana | 70112 | United States |
| University of North Carolina | Chapel Hill | North Carolina | 27599-7600 | United States |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27157 | United States |
| Saint Christopher's Hospital for Children | Philadelphia | Pennsylvania | 19134 | United States |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | United States |
| Evan Hayes Burn Center, Virginia Commonwealth University | Richmond | Virginia | 23219 | United States |
| University of Washington Regional Burn Center at Harborview Medical Center | Seattle | Washington | 98104 | United States |
| FG001 | Mepilex® Ag Wound Dressing | Mepilex® Ag Wound Dressing Conventional autografting (only when indicated) Mepilex® Ag Wound Dressing: Application of Mepilex® Ag Wound Dressing Conventional autografting (only when indicated): When indicated, conventional autografting in accordance with Investigator's standard practice |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | RECELL® Autologous Cell Harvesting Device | RECELL + Telfa™ Clear and Xeroform™ dressings Conventional autografting (only when indicated) RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings. Conventional autografting (only when indicated): When indicated, conventional autografting in accordance with Investigator's standard practice |
| BG001 | Mepilex® Ag Wound Dressing | Mepilex® Ag Wound Dressing Conventional autografting (only when indicated) Mepilex® Ag Wound Dressing: Application of Mepilex® Ag Wound Dressing Conventional autografting (only when indicated): When indicated, conventional autografting in accordance with Investigator's standard practice |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence of Index Burns With Day 10 Healing | Day 10 healing will be evaluated by an observer blinded to treatment allocation with confirmation at Day 28 | Posted | Count of Participants | Participants | 10 Days post-treatment |
|
|
| ||||||||||||||||||||||||||||||
| Secondary | Incidence of Day 21 Healing of the Index Burn | Incidence of Day 21 healing of the Index Burn confirmed on Day 28 | Posted | Count of Participants | Participants | Day 21, confirmed on Day 28 |
|
| |||||||||||||||||||||||||||||||
| Secondary | Incidence of Conventional Autografting to Achieve Healing of the Index Burn | Incidence of conventional autografting to achieve healing of the Index Burn | Posted | Count of Participants | Participants | Through Day 28 |
|
|
1 year
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | RECELL® Autologous Cell Harvesting Device | RECELL + Telfa™ Clear and Xeroform™ dressings Conventional autografting (only when indicated) RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings. Conventional autografting (only when indicated): When indicated, conventional autografting in accordance with Investigator's standard practice | 0 | 13 | 1 | 13 | 6 | 13 |
| EG001 | Mepilex® Ag Wound Dressing | Mepilex® Ag Wound Dressing Conventional autografting (only when indicated) Mepilex® Ag Wound Dressing: Application of Mepilex® Ag Wound Dressing Conventional autografting (only when indicated): When indicated, conventional autografting in accordance with Investigator's standard practice | 0 | 6 | 1 | 6 | 3 | 6 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Impaired Healing | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Injury | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Impaired Healing | General disorders | Systematic Assessment |
| ||
| Pain | General disorders | Systematic Assessment |
| ||
| Community Acquired Infection | Infections and infestations | Systematic Assessment |
| ||
| Skin Infection | Infections and infestations | Systematic Assessment |
| ||
| Injury | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Hypertrophic Scar | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Pruritus | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Skin Exfoliation | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Elizabeth Kirshner | AVITA Medical | 661-877-6869 | ekirshner@avitamedical.com |
| Jul 9, 2024 |
| Prot_SAP_002.pdf |
| ID | Term |
|---|---|
| D002056 | Burns |
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|